Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice

Annals of Neurology

Volumn 53, Issue 6, 2003, Pages 788-796

  Volpicelli Daley, Laura A ^a   Duysen, Ellen G ^b   Lockridge, Oksana ^b   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID; ATROPINE; CHOLINESTERASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; OXOTREMORINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; BRAIN CORTEX; CELL SURFACE; CELLULAR DISTRIBUTION; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; DENDRITE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SPECIFICITY; HIPPOCAMPUS; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; COGNITION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; MALE; MICE; MICE, KNOCKOUT; MUSCARINIC AGONISTS; RECEPTORS, MUSCARINIC;

EID: 0038103811     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10589     Document Type: Article

References (46)

1. Burns A, Whitehouse P, Arendt T, Forsti H. Alzheimer's discase in senile dementia: loss of neurones in the basal forebrain: Whitehouse P, Price D, Struble R, Clarke A, Coyle J, Delong M. Science 1982;215:1237-1239. Int J Geriatr Psychiatry 1997;12:7-10.
2. Burns A, Whitehouse P, Arendt T, Forsti H. Alzheimer's discase in senile dementia: loss of neurones in the basal forebrain: Whitehouse P, Price D, Struble R, Clarke A, Coyle J, Delong M. Science 1982;215:1237-1239. Int J Geriatr Psychiatry 1997;12:7-10.
3. Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998;51:S36-S44; discussion, S65-S67.
4. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
5. Jerusalinsky D, Kornisiuk E, Izquierdo I. Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Neurochem Res 1997;22:507-515
6. Hellstrom-Lindahl E. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 2000;393:255-263.
7. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey Al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891
8. Levey Al, Kitt CA, Simonds WF, et al. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991;11:3218-3226.
9. Levey Al, Edmunds SM, Koliatsos V, et al. Expression of ml-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 1995;15:4077-4092.
10. Koenig JA, Edwardson JM. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 1997;18:276-287.
11. Xie W, Stribley JA, Chatonnet A, et al. Postnatal developmental delay and supersensitivity to organophosphate in genetargeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000;293:896-902.
12. Duysen EG, Stribley JA, Fry DL, et al. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res Dev Brain Res 2002;137:43-54.
13. Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627-639.
14. Gilmor ML, Nash NR, Roghani A, et al. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J Neurosci 1996;16:2179-2190.
15. Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999;47:719-730.
16. Rouse ST, Edmunds SM, Yi H, et al. Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. Neurosci Lett 2000;284:182-186.
17. Hajos N, Papp EC, Acsady L, et al. Distinct interneuron types express m2 muscarinic receptor immunoreactivity on their dendrites or axon terminals in the hippocampus. Neuroscience 1998;82:355-376.
18. Rouse ST, Levey Al. Expression of m1-m4 muscarinic acetylcholine receptor immunoreactivity in septohippocampal neurons and other identified hippocampal afferents. J Comp Neurol 1996;375:406-416.
19. Rouse ST, Gilmor ML, Levey Al. Differential presynaptic and postsynaptic expression of m1-m4 muscarinic acetylcholine receptors at the perforant pathway/granule cell synapse. Neuroscience 1998;86:221-232.
20. Rouse ST, Marino MJ, Potter LT, et al. Muscarinic receptor subtypes involved in hippocampal circuits. Life Sci 1999;64:501-509.
21. Marino MJ, Rouse ST, Levey Al, et al. Activation of the genetically defined m1 muscarinic receptor potentiates N-methylD-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA 1998;95:11465-11470.
22. Berkeley JL, Gomeza J, Wess J, et al. M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci 2001;18:512-524.
23. Zhang W, Basile AS, Gomeza J, et al. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002;22:1709-1717.
24. Adams JP, Sweatt JD. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 2002;42:135-163.
25. Mills J, Laurent Charest D, Lam F, et al. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 1997;17:9415-9422.
26. Haring R, Fisher A, Marciano D, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the ml muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem 1998;71:2094-2103.
27. Hamilton SE, Nathanson NM. The M1 receptor is required for muscarinic activation of mitogen-activated protein (MAP) kinase in murine cerebral cortical neurons. J Biol Chem 2001;276:15850-15853.
28. Selden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249-2257.
29. Maddock RJ. The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci 1999;22:310-316.
30. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
31. Bodick NC, Offen WW, Levey Al, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
32. Li B, Duysen EG, Volpicelli LA, et al. Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice. Pharmacol Biochem Behav 2003;74:977-986.
33. Hamilton SE, Loose MD, Qi M, et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 1997;94:13311-13316.
34. McCormick DA, Prince DA. Two types of muscarinic response to acetylcholine in mammalian cortical neurons. Proc Natl Acad Sci USA 1985;82:6344-6348.
35. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M(1) muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-58.
36. Bullock R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 2002;180:135-139.
37. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002:6-19.
38. Olianas MC, Onali P, Schwartz JP, et al. The muscarinic receptor adenylate cyclase complex of rat striatum: desensitization following chronic inhibition of acetylcholinesterase activity. J Neurochem 1984;42:1439-1443.
39. Gazit H, Silman I, Dudai Y. Administration of an organophosphate causes a decrease in muscarinic receptor levels in rat brain. Brain Res 1979;174:351-356.
40. Liste I, Bernard V, Bloch B. Acute and chronic acetylcholinesterase inhibition regulates in vivo the localization and abundance of muscarinic receptors m2 and m4 at the cell surface and in the cytoplasm of striatal neurons. Mol Cell Neurosci 2002;20:244-256.
41. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, eds. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000:181-226.
42. Keith DE, Anton B, Murray SR, et al. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998;53:377-384.
43. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23-49.
44. Tammenmaa LA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002;3:CD000207.
45. Shannon HE, Rasmussen K, Bymaster FP, et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 2000;42:249-259.
46. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002;15:445-450.